Skip to main content
All lobbying filings

Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. filed a Q3 report for Jazz Pharmaceuticals, Inc. on October 20, 2026.

Lobbying for Jazz Pharmaceuticals, Inc.

As filed: JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.

All filings by Jazz Pharmaceuticals, Inc. · Everything Jazz Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$550,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act Legislation Related to the Repeal or Reform of Orphan Cures Section 232 Tariffs

 Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem